Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Sezary Syndrome 2Pancreatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Glioma 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2

Interventions

Doxorubicin 13Zidovudine 12Vincristine 11Bleomycin 8Cyclophosphamide 7Interferon alpha-2 6Etoposide 5Dexamethasone 5sargramostim 4Specimen Handling 4Methotrexate 4Magnetic Resonance Spectroscopy 4Leucovorin 4Filgrastim 4Cytarabine 4Rituximab 3Prednisone 3Nivolumab 3interferon alfa-n1 2cabozantinib 2Thalidomide 2Isotretinoin 2Interleukin-2 2Fluorouracil 2Didanosine 2Bortezomib 2Biopsy 2Allopurinol 2prednylidene 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × HIV Infections × pembrolizumab × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡